NCT04879953View on ClinicalTrials.gov

Effect of the PIPAC on the Survival Rate of Patients With Peritoneal Carcinomatosis of Gastric Origin

CompletedOBSERVATIONAL
Enrollment

46

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

August 30, 2020

Study Completion Date

December 31, 2020

Conditions
Carcinomatosis, Peritoneal
Interventions
DRUG

PIPAC with systemic chemotherapy

PIPAC procedures were performed every 6 to 8 weeks, alternating with systemic chemotherapy, replacing a cycle of intravenous chemotherapy.

DRUG

Systemic chemotherapy alone

Intravenous chemotherapy

Trial Locations (1)

Unknown

CHUGA, Grenoble

All Listed Sponsors
lead

Association Francaise de Chirurgie

OTHER

NCT04879953 - Effect of the PIPAC on the Survival Rate of Patients With Peritoneal Carcinomatosis of Gastric Origin | Biotech Hunter | Biotech Hunter